Accustem Sciences (ACUT) Return on Capital Employed (2022 - 2026)
Accustem Sciences (ACUT) posted quarterly Return on Capital Employed of 46.52% for Q1 2026, down 230.0% year-over-year from 35.79% in Q1 2025, and down 10.2% quarter-over-quarter from 51.81% in Q4 2025.
Accustem Sciences (ACUT) Return on Capital Employed (2022 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Return on Capital Employed for 5 consecutive years, with 46.52% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 230.0% year-over-year to 46.52%; the TTM figure through Mar 2026 stood at 46.52% (down 230.0% YoY), while the FY2025 annual figure was 42.31%, down 370.0% from the prior year.
- Return on Capital Employed eased to 46.52% in Q1 2026 per ACUT's latest filing, from 51.81% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 630.89% in Q1 2023 and bottomed at 1855.26% in Q4 2022.
- Historically, Return on Capital Employed has averaged 44.52% across 5 years, with a median of 51.81% in 2025.
- Annual changes were most pronounced in 2023 — Return on Capital Employed surged 195531 bps — and 2024, when it slumped 56326 bps.
- Accustem Sciences' Return on Capital Employed stood at 1855.26% in 2022, then soared by 105 bps to 100.05% in 2023, then plunged by 54 bps to 45.79% in 2024, then rose by 13 bps to 51.81% in 2025, then declined by 10 bps to 46.52% in 2026.
- Business Quant data shows ACUT's Return on Capital Employed at 46.52% in Q1 2026, 51.81% in Q4 2025, and 55.83% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - | 39.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.52% |
| Dec 31, 2025 | 51.81% |
| Sep 30, 2025 | 55.83% |
| Jun 30, 2025 | 60.09% |
| Mar 31, 2025 | 48.82% |
| Dec 31, 2024 | 45.79% |
| Sep 30, 2024 | 43.42% |
| Jun 30, 2024 | 56.32% |
| Mar 31, 2024 | 67.63% |
| Dec 31, 2023 | 100.05% |
| Sep 30, 2023 | 155.92% |
| Jun 30, 2023 | 218.35% |
| Mar 31, 2023 | 630.89% |
| Dec 31, 2022 | -1,855.26% |
| Sep 30, 2022 | -281.25% |
| Jun 30, 2022 | -118.67% |
| Mar 31, 2022 | -83.10% |